AU729502B2 - Oral administration of chicken yolk antibodies to treat disease - Google Patents

Oral administration of chicken yolk antibodies to treat disease Download PDF

Info

Publication number
AU729502B2
AU729502B2 AU47419/97A AU4741997A AU729502B2 AU 729502 B2 AU729502 B2 AU 729502B2 AU 47419/97 A AU47419/97 A AU 47419/97A AU 4741997 A AU4741997 A AU 4741997A AU 729502 B2 AU729502 B2 AU 729502B2
Authority
AU
Australia
Prior art keywords
mediator
egg
antibodies
cell
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU47419/97A
Other languages
English (en)
Other versions
AU4741997A (en
Inventor
Marilyn A. Coleman
Mitchell V. Kaminski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ovimmune Inc
Original Assignee
Ovimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovimmune Inc filed Critical Ovimmune Inc
Publication of AU4741997A publication Critical patent/AU4741997A/en
Application granted granted Critical
Publication of AU729502B2 publication Critical patent/AU729502B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/02—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU47419/97A 1996-10-02 1997-10-02 Oral administration of chicken yolk antibodies to treat disease Ceased AU729502B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72440896A 1996-10-02 1996-10-02
US08/724408 1996-10-02
PCT/US1997/017722 WO1998014209A1 (fr) 1996-10-02 1997-10-02 Administration orale d'anticorps a base de jaune d'oeuf de poule pour le traitement de maladies

Publications (2)

Publication Number Publication Date
AU4741997A AU4741997A (en) 1998-04-24
AU729502B2 true AU729502B2 (en) 2001-02-01

Family

ID=24910322

Family Applications (1)

Application Number Title Priority Date Filing Date
AU47419/97A Ceased AU729502B2 (en) 1996-10-02 1997-10-02 Oral administration of chicken yolk antibodies to treat disease

Country Status (7)

Country Link
EP (1) EP0930891A4 (fr)
JP (1) JP2001501622A (fr)
KR (1) KR20000048855A (fr)
AU (1) AU729502B2 (fr)
CA (1) CA2267421A1 (fr)
NZ (1) NZ335170A (fr)
WO (1) WO1998014209A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395273B1 (en) * 1998-06-10 2002-05-28 Promega Corporation Prevention and treatment of inflammatory bowel disease
WO1999064069A1 (fr) * 1998-06-10 1999-12-16 Ophidian Pharmaceuticals, Inc. Anticorps anticytokiniques utilises en prevention et traitement de maladies intestinales inflammatoires
US7494652B1 (en) * 1998-06-10 2009-02-24 Promega Corporation Treatment of sepsis
DE19910159A1 (de) * 1999-02-26 2000-09-14 Rosemarie Heis Spezifische lgY-Eidotterantikörper, ihre Gewinnung und ihre Verwendung
US6346247B1 (en) * 1999-10-28 2002-02-12 Promega Corporation Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies
US7355092B2 (en) 1999-12-27 2008-04-08 Ronald Marquardt Genetic vaccines for the production of chicken egg-yolk antibodies against enterotoxigenic Escherichia coli and other pathogens
KR100364198B1 (ko) * 2000-06-09 2002-12-12 영농조합법인다한 헬리코박터 파이로리에 대한 개선된 ｌｇＹ 생성의유도방법 및 이에 의해 제조된 계란
CA2437095A1 (fr) * 2001-01-30 2002-10-10 The Lauridsen Group, Incorporated Procedes et compositions destines a moduler le systeme immunitaire des animaux
BR0206869A (pt) * 2001-01-30 2007-01-02 Lauridsen Group Inc método para o tratamento de um animal sofrendo de um estado doentio de disfunção imune associado com nìveis alterados de igg ou tnf-delta, composição farmacêutica para o tratamento de distúrbios auto-imunes associados com elevados igg e/ou tnf-delta ou para a potenciação de protocolos de vacina, e método para o tratamento de estado doentio associado com disfunção imune em um animal
CA2339436A1 (fr) * 2001-03-15 2002-09-15 Josee Harel Production d'anticorps contre les facteurs de virulence associes aux souches d'escherichia coli aeec, et leur utilisation
KR20030026502A (ko) * 2001-09-26 2003-04-03 배만종 다기능성(抗헬리코박터 파이롤리 항체, 저콜레스테롤,高디에이취에이 함유) 일반계란, 토종계란 및 청색계란생산방법
KR100392566B1 (ko) * 2001-11-13 2003-07-23 주식회사 에그 바이오택 여드름질환에 관한 프로피오니박테리움 아크네스, 스타필로코커스 에피더미디스, 대장균에 대한 항-혼합균 공유 복합특수면역단백질(IgY) 함유 계란생산 및 항-혼합균 공유 복합특수면역단백질(IgY) 제조방법
CA2438698C (fr) * 2001-12-28 2013-12-17 Camas, Incorporated Inhibiteur d'adherence d'immunogenes et sa methode d'elaboration et d'utilisation
KR100489615B1 (ko) * 2002-01-30 2005-05-17 주식회사 단바이오텍 리스테리아 모노사이토제네스 감염의 예방 및 치료를 위한항체, 이를 포함하는 알 및 이들의 제조방법
KR20030079382A (ko) * 2002-04-04 2003-10-10 최태부 소화 효소-지방산 복합체를 항원으로하여 생산된 항체 및이의 이용
WO2003105873A1 (fr) * 2002-06-13 2003-12-24 株式会社 トーカイビケン Preparation sur mesure et procede de production de ladite preparation
KR20040005540A (ko) * 2002-07-10 2004-01-16 백반석 장염과 식중독의 원인물질에 대한 복합 특이 난황 항체의생산 방법
KR20040005539A (ko) * 2002-07-10 2004-01-16 백반석 이온수와 당을 이용한 계란 난황내의 수용성 특수면역단백질의 분리 및 제조
KR20040005541A (ko) * 2002-07-10 2004-01-16 선우선영 여드름 원인물질에 대한 효과적인 여러형태의 복합특이난황항체의 생산법
ES2393674T3 (es) * 2003-11-14 2012-12-27 Brigham And Women's Hospital, Inc. Métodos para modular la inmunidad
WO2005099753A1 (fr) * 2004-04-16 2005-10-27 The Govenors Of The University Of Alberta Anticorps de jaune d'oeuf anti-gluten pour le traitement de la maladie caeliaque
EP1723951A1 (fr) * 2005-04-21 2006-11-22 N.V. Nutricia Supplément nutritionnel avec des oligosaccharides pour une catégorie de patients avec HIV
JP2007084495A (ja) * 2005-09-22 2007-04-05 Daikin Ind Ltd ウイルス感染細胞処理方法
JP2007082486A (ja) * 2005-09-22 2007-04-05 Daikin Ind Ltd ウイルスが感染した生物由来物の処理方法、感染ウイルスに対する処理済細胞、感染ウイルスに対する処理済組織、感染ウイルスに対する処理済臓器
NZ575918A (en) * 2006-08-31 2012-03-30 A C N 135 493 391 Pty Ltd As Trustee For Conca Unit Trust Treatment and/or prevention of non-infectious medical conditions using antibody-containing milk or egg products
WO2008051980A2 (fr) 2006-10-25 2008-05-02 Wisconsin Alumni Research Foundation Procédés pour réduire l'absorption de phosphate
US8282928B2 (en) 2007-05-30 2012-10-09 The Governors Of The University Of Alberta Anti-gluten egg yolk antibodies for the treatment of celiac disease
ES2742734T3 (es) 2010-11-23 2020-02-17 Pantheryx Inc Composiciones y procedimientos para el tratamiento en aplicaciones clínicas de espectro general, no diferenciadas o mixtas
US20130011410A1 (en) * 2011-07-07 2013-01-10 Amicus Biotech Inc. Egg White Antibodies for Prevention and Treatment of Specific Localized Intestinal Infections and Diseases Associated with a Pathogenic Organism or Molecule
KR101911229B1 (ko) 2011-08-19 2018-10-24 임모탈 스피릿 리미티드 항체 및 항체 함유 조성물
CN106749650B (zh) * 2016-12-19 2021-06-25 姚善龙 抗感冒病毒及肺链菌、葡萄球菌复合IgY抗体制备方法及其应用
KR102200721B1 (ko) * 2019-11-18 2021-01-13 (주)애드바이오텍 연어 리케차성 패혈증 예방 또는 치료용 난황항체의 제조방법
CN112957464A (zh) * 2021-02-24 2021-06-15 江秀坤 一种将鸡卵黄免疫球蛋白制备成润喉保健产品的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550019A (en) * 1978-03-22 1985-10-29 South Africa Inventions Development Corporation Manufacture and use of fowl egg antibodies
US4748018A (en) * 1984-02-07 1988-05-31 Stolle Research & Development Corp. Method of passive immunization of mammals using avian antibody
US5258178A (en) * 1990-07-30 1993-11-02 Abbott Laboratories Method and product for the treatment of gastric disease
US5420253A (en) * 1993-09-09 1995-05-30 Willmar Poultry Company, Inc. Method for purifying egg yolk immunoglobulins
US5585098A (en) * 1993-11-23 1996-12-17 Ovimmune, Inc. Oral administration of chicken yolk immunoglobulins to lower somatic cell count in the milk of lactating ruminants
DE19504755C2 (de) * 1995-02-02 1997-04-30 Panagiotis Tsolkas Aviäre, vitelline, gegen HIV-Antigene gerichtete Antikörper

Also Published As

Publication number Publication date
AU4741997A (en) 1998-04-24
EP0930891A1 (fr) 1999-07-28
KR20000048855A (ko) 2000-07-25
JP2001501622A (ja) 2001-02-06
WO1998014209A1 (fr) 1998-04-09
NZ335170A (en) 2001-08-31
EP0930891A4 (fr) 2001-07-04
CA2267421A1 (fr) 1998-04-09

Similar Documents

Publication Publication Date Title
AU729502B2 (en) Oral administration of chicken yolk antibodies to treat disease
JP2698779B2 (ja) トリの抗体を用いた哺乳動物の受動免疫化
KR102037885B1 (ko) 광범위한, 미확인 또는 혼합된 임상적 적용에서 치료용 조성물들 및 방법들
Tsubokura et al. Oral administration of antibodies as prophylaxis and therapy in Campylobacter jejuni‐infected chickens
WO1997020577A1 (fr) Formulation therapeutique amelioree et procede correspondant
EP0706400A1 (fr) Formulation et methode therapeutiques
Wiedemann et al. Chicken egg antibodies for prophylaxis and therapy of infectious intestinal diseases: V. in vivo studies on protective effects against Escherichia coli diarrhea in pigs
KR910005409B1 (ko) 계란으로 부터의 특이적항체함유재료의 제조방법
US20020044942A1 (en) Transfer factor composition and process for producing same
JPH0657663B2 (ja) 多機能特異的抗体の製造方法
JP2022513337A (ja) 動物の腸管感染症及び急性下痢を治療する組成物及び方法
US20040202660A1 (en) Methods and compositions for treatment of immune dysfunction disorders
PL214224B1 (pl) Doustna forma koncentratu nie - hiperimmunizowanych nie-specyficznych immunoglobulin oraz suplement diety
JPH07252165A (ja) 免疫モジュレータおよびその製造方法
US20070264264A1 (en) Method and composition for conferring immunity in mammals
US20040258664A1 (en) Multifunctional complex for targeting specific phagocytosis of a target agent
Landon et al. Therapeutic antibodies
WO1996010420A1 (fr) Composition et traitement d'hyperimmunisation a l'aide de bacteries non tuees thermiquement
US20240199723A1 (en) Hyperimmunized egg product for treating or preventing alcoholic liver disease and graft-versus-host disease
AU673589B2 (en) Therapeutic formulation and method
Yadav et al. PRODUCTION OF POLYCLONAL ANTIBODIES AGAINST INDIAN CATTLE TICK RHIPICEPHALUS MICROPLUS SALIVA TOXINS AND ITS EFFICACY IN REVERSAL OF TOXIC EFFECTS IN ALBINO MICE
Trisunuwati et al. Animal Health and Disease Prevention
JPH05255113A (ja) 特異的抗体及びそれを配合してなるエビ類感染症防除組成物
Roth Basic Immunology and Principles of Vaccination

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired